ORPHA:206594
Subacute inflammatory demyelinating polyneuropathy
Also known as: Subacute inflammatory demyelinating polyradiculoneuropathy
Publications
334
65.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,145
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare neuroinflammatory disease characterized by muscular weakness with impaired sensation, absent or diminished tendon reflexes and elevated cerebrospinal fluid (CSF) protein content. Subacute inflammatory demyelinating polyneuropathy (SIDP) is an intermediate form between Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016102
- UMLS:C0456517
Additional Mondo synonyms (2)
SIDP · subacute inflammatory demyelinating polyradiculoneuropathy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
334 matched papers (176 in last 10 years) Source
- Phenotype characterisedPresent
40 HPO annotations (e.g. Decreased nerve conduction velocity; Muscle weakness; Increased CSF protein concentration) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 54 for broader category demyelinating polyneuropathy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
40
Associated phenotypes · MONDO:0016102
- Decreased nerve conduction velocity
- Muscle weakness
- Increased CSF protein concentration
- Demyelinating motor neuropathy
- Limited elbow flexion
Showing 5 of 40 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
334
334 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
334 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
176 in the last 10 years · medium confidence · 65.9th percentile (publications denominator)
Phrase hits: 334 · MeSH hits: 0
Who's working on it?
1,145
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01SANDROCK ALFRED6 papers · 2012Papers in Europe PMC
- 02Kim YH4 papers · 2023
Biomedical Omics Group, Korea Basic Science Institute, Cheongju, Chungbuk, 28119, Republic of Korea.
Papers in Europe PMC - 03Koszewicz M4 papers · 2026
Department of Neurology, Wroclaw Medical University, Borowska 213 Str., 50-556 Wroclaw, Poland.
Papers in Europe PMC - 04Li Y4 papers · 2024
Department of Physiology, School of Life Science, China Medical University, Shenyang, 110122, People's Republic of China.
Papers in Europe PMC - 05Sharma S4 papers · 2022
Department of Neurology, Indira Gandhi Medical College and Hospital, Shimla, Himachal Pradesh, India.
Papers in Europe PMC - 06Zhang G4 papers · 2026
Department of Neurology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Papers in Europe PMC - 07Choi BO3 papers · 2022
Department of Neurology, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea.
Papers in Europe PMC - 08Dziadkowiak E3 papers · 2026
Department of Neurology, Wroclaw Medical University, Borowska 213 Str., 50-556 Wroclaw, Poland.
Papers in Europe PMC - 09Gao T3 papers · 2026
Department of Neurology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Papers in Europe PMC - 10Jo YR3 papers · 2023
Peripheral Neuropathy Research Center (PNRC), Dong-A University College of Medicine, Busan, 49201, Republic of Korea.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 54 trials are registered for demyelinating polyneuropathy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
54 interventional trials matched demyelinating polyneuropathy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: demyelinating polyneuropathy
54
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06714838·RECRUITING·Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP·Matched via name phrase
- NCT07337785·RECRUITING·CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Conditions: Relapsing or Refractory Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Autoimmune Encephalitis (AE)·Matched via name phrase
- NCT07032662·RECRUITING·Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT04929236·RECRUITING·Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT04589299·RECRUITING·Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
Conditions: CIDP - Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT06858579·RECRUITING·A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT07392229·RECRUITING·Zanubritnib and Anti-MAG Neuropathy
Conditions: Anti-MAG IgM-associated Demyelinating Polyneuropathy·Matched via name phrase
- NCT07091630·RECRUITING·A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy · CIDP · Chronic Inflammatory Demyelinating Polyradiculoneuropathy·Matched via name phrase
- NCT04881682·RECRUITING·Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: CIDP·Matched via name phrase
- NCT06752356·RECRUITING·A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT07526493·RECRUITING·Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Conditions: Multiple Sclerosis (MS) · Neuromyelitis Optica Spectrum Disorder (NMOSD) · Autoimmune Encephalitis (AE) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)·Matched via name phrase
- NCT06920004·RECRUITING·A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy · CIDP · CIDP - Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT06290141·RECRUITING·A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy·Matched via name phrase
- NCT07072676·ENROLLING BY INVITATION·The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Conditions: Inclusion Body Myositis · Myotonic Dystrophy 1 · Myotonic Dystrophy 2 · Facio-Scapulo-Humeral Dystrophy·Matched via name phrase
- NCT06858722·NOT YET RECRUITING·Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Subacute inflammatory demyelinating polyneuropathy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Subacute inflammatory demyelinating polyneuropathy" OR "Subacute inflammatory demyelinating polyradiculoneuropathy"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Subacute inflammatory demyelinating polyneuropathy" OR "Subacute inflammatory demyelinating polyradiculoneuropathy"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"demyelinating polyneuropathy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: SIDP
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:21:29.511Z
